Neotropix
Malvern · Founded 2003
About Neotropix
Neotropix, Inc., a biotechnology company, develops and commercializes systemically deliverable oncolytic viruses for the treatment of neuroendocrine cancers. It develops NTX010, a naturally-occurring virus that attacks and kills neuroendocrine cancers, such as small cell lung cancer, small cell carcinomas originating in other organs, carcinoid, neuroblastoma, and certain other neuroendocrine cancers. The company was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Company Facts
- Founded: 2003
- Legal name: Neotropix Inc
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $11.4M
- Last round: Series Unknown (May 2009)
- Website: neotropix.com
- Phone: +1 610-296-8660
Social Profiles
Canonical: https://fsome.com/organization/neotropix-8441757 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.